Amgen Inc. (NASDAQ:AMGN):
Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study.
The company is trading down since yesterday’s close of $171.63.
Amgen Inc. also recently declared a dividend paid on Thursday the 8th of September 2016. The dividend payment was $1.000 per share for the quarter or $4.00 annualized. This dividend represents a yeild of $2.29 which is the dividend as a percentage of the current share price. The ex-dividend date was Monday the 15th of August 2016.
Shares last traded at $169.71 barely below the 50 day moving average which is $172.07 and a bit higher than the 200 day moving average of $160.76. The 50 day moving average went down by -1.37% and the 200 day average went up by +5.57%.
The P/E ratio is currently 17.37 and the market cap of the company is 127.00B. As of the last earnings report the EPS was $9.77 and is estimated to be $11.36 for the current year with 748,360,000 shares now outstanding. Next quarter’s EPS is forecasted to be $2.82 and the next full year EPS is projected to be $12.47.
Investors are more bearish on shares of Amgen Inc. of late looking at the motion in short interest. The stock recorded a rise in short interest from August 31, 2016 to September 15, 2016 of 0.09%. Short shares grew from 8,005,185 to 8,720,839 over that period. The short-interest ratio increased to 3.2 and the percentage of shorted shares was 0.01% on September 15.
A few investment firms have weighed in on the company recently. September 28 investment analysts at Citigroup left the stock rating at “Neutral” and lowered the price expectation from $198.00 to $172.00. On August 26, 2016 Gabelli & Co. starting coverage on the stock by announcing an initial rating of “Hold”.
Equity analyst Bernstein initiated coverage giving it an initial rating of “Market Perform”. On April 5 analysts at BMO Capital issued its first research report on the stock with an initial rating of “Outperform” and a price target of $183.00.
Citigroup initiated coverage on AMGN with a rating of “Neutral”. On February 8 Argus Research held the company rating at “Buy” but lowered the price expectation to $185.00 from $202.00.